Literature DB >> 27818483

Regulation of Cardiac Transcription Factor GATA4 by Post-Translational Modification in Cardiomyocyte Hypertrophy and Heart Failure.

Yasufumi Katanasaka1, Hidetoshi Suzuki, Yoichi Sunagawa, Koji Hasegawa, Tatsuya Morimoto.   

Abstract

Heart failure is a leading cause of cardiovascular mortality in industrialized countries. During development and deterioration of heart failure, cardiomyocytes undergo maladaptive hypertrophy, and changes in the cellular phenotype are accompanied by reinduction of the fetal gene program. Gene expression in cardiomyocytes is regulated by various nuclear transcription factors, co-activators, and co-repressors. The zinc finger protein GATA4 is one such transcription factor involved in the regulation of cardiomyocyte hypertrophy. In response to hypertrophic stimuli such as those involving the sympathetic nervous and renin-angiotensin systems, changes in protein interaction and/or post-translational modifications of GATA4 cause hypertrophic gene transcription in cardiomyocytes. In this article, we focus on cardiac nuclear signaling molecules, especially GATA4, that are promising as potential targets for heart failure therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27818483     DOI: 10.1536/ihj.16-404

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  8 in total

1.  Steroid receptor coactivator-2 (SRC-2) coordinates cardiomyocyte paracrine signaling to promote pressure overload-induced angiogenesis.

Authors:  Ji Ho Suh; Li Lai; Deokhwa Nam; Jong Kim; Juyeon Jo; George E Taffet; Eunah Kim; Jason T Kaelber; Hyun-Kyoung Lee; Mark L Entman; John P Cooke; Erin L Reineke
Journal:  J Biol Chem       Date:  2017-11-10       Impact factor: 5.157

Review 2.  Advances in the relationship between Kruppel-like factor 15 and cardiovascular disease research.

Authors:  Yang Yuping; Chen Hua; Zhou Qing
Journal:  Cardiovasc Endocrinol Metab       Date:  2018-05-16

3.  Differential Activation of P-TEFb Complexes in the Development of Cardiomyocyte Hypertrophy following Activation of Distinct G Protein-Coupled Receptors.

Authors:  Ryan D Martin; Yalin Sun; Sarah MacKinnon; Luca Cuccia; Viviane Pagé; Terence E Hébert; Jason C Tanny
Journal:  Mol Cell Biol       Date:  2020-06-29       Impact factor: 4.272

Review 4.  Towards Understanding the Gene-Specific Roles of GATA Factors in Heart Development: Does GATA4 Lead the Way?

Authors:  Boni A Afouda
Journal:  Int J Mol Sci       Date:  2022-05-09       Impact factor: 6.208

5.  Overexpression of GATA4 enhances the antiapoptotic effect of exosomes secreted from cardiac colony-forming unit fibroblasts via miRNA221-mediated targeting of the PTEN/PI3K/AKT signaling pathway.

Authors:  Chunshu Hao; Zhengri Lu; Yuanyuan Zhao; Zhong Chen; Chengxing Shen; Genshan Ma; Lijuan Chen
Journal:  Stem Cell Res Ther       Date:  2020-06-26       Impact factor: 6.832

6.  Multimerization of the GATA4 transcription factor regulates transcriptional activity and cardiomyocyte hypertrophic response.

Authors:  Satoshi Shimizu; Yoichi Sunagawa; Naruto Hajika; Natsumi Yorimitsu; Yasufumi Katanasaka; Masafumi Funamoto; Yusuke Miyazaki; Nurmila Sari; Kana Shimizu; Koji Hasegawa; Tatsuya Morimoto
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

7.  Phosphorylation of GATA4 at serine 105 is required for left ventricular remodelling process in angiotensin II-induced hypertension in rats.

Authors:  Alicia Jurado Acosta; Jaana Rysä; Zoltan Szabo; Anne-Mari Moilanen; Raisa Serpi; Heikki Ruskoaho
Journal:  Basic Clin Pharmacol Toxicol       Date:  2020-03-09       Impact factor: 4.080

8.  12-O-Tetradecanoylphorbol-13-acetate increases cardiomyogenesis through PKC/ERK signaling.

Authors:  Katarzyna Anna Radaszkiewicz; Deborah Beckerová; Lucie Woloszczuková; Tomasz Witold Radaszkiewicz; Petra Lesáková; Olga Vondálová Blanářová; Lukáš Kubala; Petr Humpolíček; Jiří Pachernik
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.